The company anticipates netting $64.1 million in proceeds from the offering.
The firm sold 15,686,000 shares of common stock at a price of $2.20 per share.
The firm is selling nearly 1.2 million shares at $1.99 per share in a direct offering.
Opko said it may use some of the proceeds to make additional acquisitions.
Vermillion anticipates net proceeds of $20.2 million from the offering of 4 million common shares.
The company has lowered its price target to up to $29.9 million from as much as $33.9 million.
The company said the offering is expected to close mid-February.
The firm said that the overallotment option of 2.1 million shares was exercised, resulting in net proceeds of around $90.5 million from the offering.
The firm will use the funds to support ongoing testing and development of its trisomy 21 non-invasive, pre-natal test.
The firm is considering selling off its genetic testing and biomarker development business, including its CLIA lab.
A new report offers ways for small, society publishers to transition to Plan S standards, ScienceInsider says.
A gas explosion sparked a fire at a Russian laboratory that stores dangerous pathogens, the Guardian reports.
Researchers turn to protein analysis to examine an ancient rhino sample, Smithsonian.com reports.
In PNAS this week: C2CD4A gene involved in insulin secretion, chromosome rearrangements in recurring S. aureus infections, and more.